SCIENTIA ADVISORS: NEWS
Release Date: 02/09/2007Scientia Advisors Management Consultant and Managing Partner, Harry Glorikian, to Facilitate an Executive Strategy Panel Titled: Diagnostic Wish Lists.
Harry Glorikian, Managing Partner and Management Consultant of Scientia Advisors, will be Facilitate an Executive Strategy Panel Titled: Diagnostic Wish Lists. The topics discussed will be:
Panelists:
Ronald M. Krauss, M.D., Director, Atherosclerosis Research, Children's Hospital Oakland Research Institute (CHORI), and Senior Scientist, Department of Genome Science, Lawrence Berkeley National Laboratory, Adjunct Professor, Department of Nutritional Sciences, UC Berkeley
Yerem Yeghiazarian, Ph.D., Assistant Professor of Medicine, Interventional Cardiology, and Director, Stem Cell Program, University of California, San Francisco
Harry Glorikian’s experience allows him to cover a broad range of areas within life sciences. His direct experience in sales, marketing, business development, and intellectual property combined with his technical and market knowledge provides unique and insightful perspectives. Harry has 15 years of experience in the life sciences developing and executing key strategic acquisitions and licensing arrangements targeting revenue growth channels. Harry currently leads Scientia, including the management of consulting teams, new business development, and intellectual capital development. His client engagements have involved comprehensive go-to-market plans in the areas of diagnostics, genomic, proteomics, cell biology, cellular therapy and consumables & services groups. His clients include both emerging innovators and global market leaders.
For more information please visit: www.tri-conference.com
Click here to download PDF version- What assays do you want from vendors or reference labs?
- What areas are of most importance:
- Dx/SC= Diagnostics and Screening
- TR= Therapy Response
- Cmp= Companion Diagnostics
- PD= Predisposition Testing
- RL= Drug Relapse Monitoring
- Is there an order that should be followed?
- Which segment gives you the most valuable piece of information?
- What advances are needed to increase Molecular Diagnostic testing?
Panelists:
Ronald M. Krauss, M.D., Director, Atherosclerosis Research, Children's Hospital Oakland Research Institute (CHORI), and Senior Scientist, Department of Genome Science, Lawrence Berkeley National Laboratory, Adjunct Professor, Department of Nutritional Sciences, UC Berkeley
Yerem Yeghiazarian, Ph.D., Assistant Professor of Medicine, Interventional Cardiology, and Director, Stem Cell Program, University of California, San Francisco
Harry Glorikian’s experience allows him to cover a broad range of areas within life sciences. His direct experience in sales, marketing, business development, and intellectual property combined with his technical and market knowledge provides unique and insightful perspectives. Harry has 15 years of experience in the life sciences developing and executing key strategic acquisitions and licensing arrangements targeting revenue growth channels. Harry currently leads Scientia, including the management of consulting teams, new business development, and intellectual capital development. His client engagements have involved comprehensive go-to-market plans in the areas of diagnostics, genomic, proteomics, cell biology, cellular therapy and consumables & services groups. His clients include both emerging innovators and global market leaders.
For more information please visit: www.tri-conference.com
